Blitz Bureau
NEW DELHI: Biological E. Limited (BE), a Hyderabad-based vaccine and pharmaceutical company, on July 30 announced that the World Health Organisation (WHO) has granted pre-qualification (PQ) status to their Novel Oral Polio Vaccine type 2 (nOPV2). nOPV2 is the 10th pre-qualified vaccine of BE.
“This next-generation live, attenuated oral vaccine significantly reduces the risk of circulating vaccine-derived poliovirus type 2 (cVDPV2) outbreaks and it is aimed at immunisation in countries that are affected by cVDPV2 outbreaks,” the company said.
The persistent threat of cVDPV2 outbreaks can be tackled with the use of nOPV2 as the vaccine of choice. With its improved genetic stability, nOPV2 has a significantly decreased chance of seeding new outbreaks in low-immunity environments as against its predecessor, the Sabin poliovirus type 2 (mOPV2) vaccine, the BE said.
Extensive clinical trials have rigorously evaluated the safety and immunogenicity of nOPV2, leading to promising results published in
